Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
clinical trials
5
×
life sciences
europe top stories
fda
national blog main
europe blog main
national
national top stories
san francisco top stories
boston blog main
boston top stories
new york top stories
san francisco blog main
abaloparatide
abbvie
alkermes
allergan
amgen
arena pharmaceuticals
billy dunn
biogen
biologic drugs
boston xcon
boulder/denver blog main
boulder/denver top stories
boulder/denver xcon
buprenorphine
cancer
cardiovascular disease
cariprazine
colorectal cancer
detroit blog main
detroit top stories
detroit xcon
digital health
drug development
drug prices
drug pricing
eisai
What
drug
5
×
medicine
5
×
fda
patients
marketing
weight
alkermes
amgen
amgen’s
antipsychotic
approval
approved
atrophy
benefits
biologic
bottleneck
cancer
carries
caveats
clinical
commonly
daily
designed
developed
development
dramatically
effect
eisai
europe
european
evrysdi
favor
fixing
flags
friday
gain
genomic
green
heart
higher
Language
unset
Current search:
medicine
×
drug
×
" clinical trials "
×
biotech
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
6 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority